Show simple item record

dc.contributor.authorValero-Grinan, Teresa M.
dc.date.accessioned2017-10-02T16:02:05Z
dc.date.available2017-10-02T16:02:05Z
dc.date.issued2014
dc.identifier.citationValero-Grinan T (2014) Editorial (Thematic Issue: Mitochondrial Biogenesis: Pharmacological Approaches). Current Pharmaceutical Design. 20(35): 5507-5509.en_US
dc.identifier.urihttp://hdl.handle.net/10454/13341
dc.descriptionyesen_US
dc.description.abstractOrganelle biogenesis is concomitant to organelle inheritance during cell division. It is necessary that organelles double their size and divide to give rise to two identical daughter cells. Mitochondrial biogenesis occurs by growth and division of pre-existing organelles and is temporally coordinated with cell cycle events [1]. However, mitochondrial biogenesis is not only produced in association with cell division. It can be produced in response to an oxidative stimulus, to an increase in the energy requirements of the cells, to exercise training, to electrical stimulation, to hormones, during development, in certain mitochondrial diseases, etc. [2]. Mitochondrial biogenesis is therefore defined as the process via which cells increase their individual mitochondrial mass [3]. Recent discoveries have raised attention to mitochondrial biogenesis as a potential target to treat diseases which up to date do not have an efficient cure. Mitochondria, as the major ROS producer and the major antioxidant producer exert a crucial role within the cell mediating processes such as apoptosis, detoxification, Ca2+ buffering, etc. This pivotal role makes mitochondria a potential target to treat a great variety of diseases. Mitochondrial biogenesis can be pharmacologically manipulated. This issue tries to cover a number of approaches to treat several diseases through triggering mitochondrial biogenesis. It contains recent discoveries in this novel field, focusing on advanced mitochondrial therapies to chronic and degenerative diseases, mitochondrial diseases, lifespan extension, mitohormesis, intracellular signaling, new pharmacological targets and natural therapies. It contributes to the field by covering and gathering the scarcely reported pharmacological approaches in the novel and promising field of mitochondrial biogenesis.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.2174/138161282035140911142118en_US
dc.rights© 2014 Bentham Science. Reproduced in accordance with the publisher's self-archiving policy. The published manuscript is available at EurekaSelect via https://doi.org/10.2174/138161282035140911142118.en_US
dc.subjectMitochondrial biogenesis; Pharmacological approaches; Treatment potential; Diseases of mitochondrial originen_US
dc.titleMitochondrial Biogenesis: Pharmacological Approachesen_US
dc.status.refereedn/aen_US
dc.typeEditorialen_US
dc.type.versionAccepted Manuscripten_US
refterms.dateFOA2018-07-29T02:53:28Z


Item file(s)

Thumbnail
Name:
Valero T Editorial (1) (3).pdf
Size:
198.0Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record